GlassScriptPhysician profile
Matthew Mcguire
NPI 1548722358
$750.16
in general payments reported to CMS, 2019-2025
14 companies · $249 in 2025
The $249 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.47 · 2022: $41.75 · 2023: $244 · 2024: $178 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $670.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $128.78 | 2023-2024 | Fintepla |
| Sk Life Science, INC. | $124.77 | 2024-2025 | |
| Immedica Pharma US, INC. | $104.14 | 2023-2024 | |
| Piramal Critical Care | $75.02 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $68.14 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $41.49 | 2023-2025 | Daybue |
| Alexion Pharmaceuticals, INC. | $37.47 | 2021 | |
| Pyros Pharmaceuticals, INC. | $28.95 | 2024 | Vigpoder |
| Catalyst Pharmaceuticals, INC. | $27.22 | 2023 | Fycompa |
| Neurelis, INC. | $24.47 | 2024 | Valtoco |
| Livanova USA, INC. | $23.80 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Orchard Therapeutics North America | $23.24 | 2025 | Lenmeldy |
| Upsher-Smith Laboratories LLC | $22.61 | 2025 | |
| Ptc Therapeutics, INC. | $20.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mcguire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.